-
Je něco špatně v tomto záznamu ?
Total body irradiation is a crucial risk factor for developing secondary carcinomas after allogeneic hematopoietic stem cell transplantation in childhood
P. Keslova, R. Formankova, P. Riha, L. Sramkova, M. Snajderova, B. Malinova, A. Luks, J. Sterba, J. Stary, P. Sedlacek,
Jazyk angličtina Země Slovensko
Typ dokumentu časopisecké články
- MeSH
- celotělové ozáření škodlivé účinky MeSH
- dítě MeSH
- homologní transplantace MeSH
- lidé MeSH
- nádory vyvolané zářením * MeSH
- příprava pacienta k transplantaci škodlivé účinky MeSH
- rizikové faktory MeSH
- sekundární malignity etiologie MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Allogeneic hematopoietic stem cell transplantation (HSCT) has become a standard part of therapy for a variety of malignant and non-malignant disorders. With improved outcomes after HSCT, increasing attention has been drawn to late complications in long-term survivors. The development of secondary malignancies is recognized as one of the most serious complications. We have evaluated data from 426 patients (272 males, 154 females) who underwent allogeneic transplantation at a median age of 7.9 years from 1989 till 2017 and were alive more than one year after transplantation for the occurrence of secondary solid tumors. We have documented the occurrence of secondary solid tumors in 20 patients (4.7%). The median duration of the development of secondary solid cancer from HSCT was 11.7 (range, 5.4-21.5 years). 18 out of 20 patients (90%) had total body irradiation (TBI) 12-14.4 Gy as a part of a conditioning regimen. All but two had transplantation for malignant disease. All patients underwent surgery and/or chemo-radiotherapy. Eighteen are alive, and two died due to the progression of their secondary malignancy. The most frequent solid cancer was thyroid carcinoma (n=9). Cumulative incidence of secondary solid cancer in all groups was 15.2±3.9%, in a group using TBI based regimen 34.7±8.9%, in non-TBI (only chemo) group was 1.5±1.1%. Overall, the cumulative incidence is statistically significantly different between the TBI based and non-TBI (chemo only) group. The incidence and number of complications following allogeneic HSCT in childhood are increasing in time. The early diagnosis of secondary malignancies is one of the key tasks of long-life multidisciplinary post-transplant care.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027901
- 003
- CZ-PrNML
- 005
- 20210114152558.0
- 007
- ta
- 008
- 210105s2020 xo f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2020_200214N131 $2 doi
- 035 __
- $a (PubMed)32657609
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Keslova, P $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 245 10
- $a Total body irradiation is a crucial risk factor for developing secondary carcinomas after allogeneic hematopoietic stem cell transplantation in childhood / $c P. Keslova, R. Formankova, P. Riha, L. Sramkova, M. Snajderova, B. Malinova, A. Luks, J. Sterba, J. Stary, P. Sedlacek,
- 520 9_
- $a Allogeneic hematopoietic stem cell transplantation (HSCT) has become a standard part of therapy for a variety of malignant and non-malignant disorders. With improved outcomes after HSCT, increasing attention has been drawn to late complications in long-term survivors. The development of secondary malignancies is recognized as one of the most serious complications. We have evaluated data from 426 patients (272 males, 154 females) who underwent allogeneic transplantation at a median age of 7.9 years from 1989 till 2017 and were alive more than one year after transplantation for the occurrence of secondary solid tumors. We have documented the occurrence of secondary solid tumors in 20 patients (4.7%). The median duration of the development of secondary solid cancer from HSCT was 11.7 (range, 5.4-21.5 years). 18 out of 20 patients (90%) had total body irradiation (TBI) 12-14.4 Gy as a part of a conditioning regimen. All but two had transplantation for malignant disease. All patients underwent surgery and/or chemo-radiotherapy. Eighteen are alive, and two died due to the progression of their secondary malignancy. The most frequent solid cancer was thyroid carcinoma (n=9). Cumulative incidence of secondary solid cancer in all groups was 15.2±3.9%, in a group using TBI based regimen 34.7±8.9%, in non-TBI (only chemo) group was 1.5±1.1%. Overall, the cumulative incidence is statistically significantly different between the TBI based and non-TBI (chemo only) group. The incidence and number of complications following allogeneic HSCT in childhood are increasing in time. The early diagnosis of secondary malignancies is one of the key tasks of long-life multidisciplinary post-transplant care.
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a nádory vyvolané zářením $7 D009381
- 650 _2
- $a sekundární malignity $x etiologie $7 D016609
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a celotělové ozáření $x škodlivé účinky $7 D014916
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Formankova, R $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Riha, P $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Sramkova, L $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Snajderova, M $u Department of Pediatrics, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Malinova, B $u Department of Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Luks, A $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Sterba, J $u Department of Pediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Stary, J $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Sedlacek, P $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University Prague, Prague, Czech Republic.
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 5 (2020), s. 1164-1169
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32657609 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152556 $b ABA008
- 999 __
- $a ok $b bmc $g 1608236 $s 1119081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 67 $c 5 $d 1164-1169 $e 20200714 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20210105
